

Disclosure Statement Pursuant to the Pink Basic Disclosure Guidelines

Revium Recovery, Inc.

10 HaMenofim St.,

Herzliya, Israel

SIC - 2080

Quarterly Report
For the Period Ending: June 30, 2022
(the "Reporting Period")

As of June 30, 2022, the number of shares outstanding of our Common Stock was:

28,050,165

As of December 31, 2021 the number of shares outstanding of our Common Stock was:

28,050,165

Indicate by check mark whether the company is a shell company (as defined in Rule 405 of the Securities Act of 1933 and Rule 12b-2 of the Exchange Act of 1934):

Yes: ☐ No: ☒

Indicate by check mark whether the company's shell status has changed since the previous reporting period:

Yes: ☐ No: ☒

Indicate by check mark whether a Change in Control¹ of the company has occurred over this reporting period:

Yes: ☐ No: ☒

1) Name and address(es) of the issuer and its predecessors (if any)

In answering this item, provide the current name of the issuer any names used by predecessor entities, along with the dates of the name changes.

¹ "Change in Control" shall mean any events resulting in:

(i) Any "person" (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) becoming the "beneficial owner" (as defined in Rule 13d-3 of the Exchange Act), directly or indirectly, of securities of the Company representing fifty percent (50%) or more of the total voting power represented by the Company's then outstanding voting securities;

(ii) The consummation of the sale or disposition by the Company of all or substantially all of the Company's assets;

(iii) A change in the composition of the Board occurring within a two (2)-year period, as a result of which fewer than a majority of the directors are directors immediately prior to such change; or

(iv) The consummation of a merger or consolidation of the Company with any other corporation, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or its parent) at least fifty percent (50%) of the total voting power represented by the voting securities of the Company or such surviving entity or its parent outstanding immediately after such merger or consolidation.

Revium Recovery, Inc., herein the “Company” or “RVRC” was incorporated on March 26, 2008 under the name OC Beverages, Inc. OC Beverage was a manufacturer of beverages and the company ceased operations in 2010.

On June 22, 2020 the Company formed a wholly owned Israeli subsidiary named Revium Recovery Ltd. (the “Subsidiary”). On December 9, 2020, the Company implemented a name change to “Revium Recovery Inc.”

The state of incorporation or registration of the issuer and of each of its predecessors (if any) during the past five years; Please also include the issuer’s current standing in its state of incorporation (e.g. active, default, inactive):

Jurisdiction: Delaware
Incorporation date: March 26, 2008
Current standing: Active

Describe any trading suspension orders issued by the SEC concerning the issuer or its predecessors since inception:

N/A

List any stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months:

In August 2021, the Company’s board of directors and the holders of a majority of the Company’s outstanding voting stock approved an amendment to the Company’s certificate of incorporation to amend the Certificate of Designation of Rights relating to the Series B Preferred Stock, par value \$0.001 per share, to (i) adjust the conversion rate thereunder from 500 shares of Common Stock to each share of Series B Preferred Stock to eight (8) shares of Common Stock to each share of Series B Preferred Stock and (ii) to delete the authorized Preferred Stock of the Company.

On November 30, 2021, 2,000,000 preferred shares were converted into 16,000,000 Common shares.

The address(es) of the issuer’s principal executive office:

10 HaMenofim St.,
Herzliya, Israel

The address(es) of the issuer’s principal place of business:

Check box if principal executive office and principal place of business are the same address: ☒

Has the issuer or any of its predecessors been in bankruptcy, receivership, or any similar proceeding in the past five years?

Yes: ☐ No: ☒

If this issuer or any of its predecessors have been the subject of such proceedings, please provide additional details in the space below:

2) Security Information

Trading symbol: RVRC
Exact title and class of securities outstanding: Common Stock
CUSIP: 76151C100
Par or stated value: \$0.001

Total shares authorized: 250,000,000 as of date: June 30, 2022
Total shares outstanding: 28,050,165 as of date: June 30, 2022
Number of shares in the Public Float²: 78,050 as of date: June 30, 2022
Total number of shareholders of record: 45 as of date: June 30, 2022

All additional class(es) of publicly traded securities (if any):

Trading symbol: RVRC
Exact title and class of securities outstanding: Series B Preferred Stock ("Series B Preferred")
CUSIP: N/A
Par or stated value: \$0.001
Total shares authorized: 10,000,000 as of date: June 30, 2022
Total shares outstanding: 0 as of date: June 30, 2022

Transfer Agent

Name: Transfer Online, Inc.
Phone: +1 (503) 227-2950
Email: info@transferonline.com
Address: 512 SE Salmon St.
Portland, OR 97214

Is the Transfer Agent registered under the Exchange Act?³ Yes: ☒ No: ☐

3) Issuance History

The goal of this section is to provide disclosure with respect to each event that resulted in any direct changes to the total shares outstanding of any class of the issuer's securities **in the past two completed fiscal years and any subsequent interim period.**

² "Public Float" shall mean the total number of unrestricted shares not held directly or indirectly by an officer, director, any person who is the beneficial owner of more than 10 percent of the total shares outstanding (a "control person"), or any affiliates thereof, or any immediate family members of officers, directors and control persons.

³ To be included in the Pink Current Information tier, the transfer agent must be registered under the Exchange Act.

Disclosure under this item shall include, in chronological order, all offerings and issuances of securities, including debt convertible into equity securities, whether private or public, and all shares, or any other securities or options to acquire such securities, issued for services. Using the tabular format below, please describe these events.

A. Changes to the Number of Outstanding Shares

Check this box to indicate there were no changes to the number of outstanding shares within the past two completed fiscal years and any subsequent periods: ☐

Shares Outstanding as of Second Most Recent Fiscal Year End: <u>Opening</u> <u>Balance</u> Date <u>December 31, 2020</u> Common: <u>4,678,050</u> Preferred: <u>2,000,000</u>			*Right-click the rows below and select "Insert" to add rows as needed.						
Date of Transaction	Transaction type (e.g. new issuance, cancellation, shares returned to treasury)	Number of Shares Issued (or cancelled)	Class of Securities	Value of shares issued (\$/per share) at Issuance	Were the shares issued at a discount to market price at the time of issuance? (Yes/No)	Individual/Entity Shares were issued to (entities must have individual with voting / investment control disclosed).	Reason for share issuance (e.g. for cash or debt conversion) -OR- Nature of Services Provided	Restricted or Unrestricted as of this filing.	Exemption or Registration Type.
<u>1/22/2021</u>	<u>New Issuance</u>	<u>625,000</u>	<u>Common Stock</u>	<u>\$0.001</u>	<u>No</u>	<u>Moshe Eichler</u>	<u>Cash</u>	<u>R</u>	<u>Exemption: Section 4(a)(2) of the Securities Act</u>
<u>1/22/2021</u>	<u>New Issuance</u>	<u>625,000</u>	<u>Common Stock</u>	<u>\$0.001</u>	<u>No</u>	<u>Schmuel Horowitz</u>	<u>Cash</u>	<u>R</u>	<u>Exemption: Section 4(a)(2) of</u>

									<u>the Securities Act</u>
<u>3/15/2021</u>	<u>New Issuance</u>	<u>125,000</u>	<u>Common Stock</u>	<u>\$0.001</u>	<u>No</u>	<u>Yochanan Cohen</u>	<u>Cash</u>	<u>R</u>	<u>Exemption: Section 4(a)(2) of the Securities Act</u>
<u>4/19/2021</u>	<u>New Issuance</u>	<u>62,500</u>	<u>Common Stock</u>	<u>\$0.001</u>	<u>No</u>	<u>Israel Klugman</u>	<u>Cash</u>	<u>R</u>	<u>Exemption: Section 4(a)(2) of the Securities Act</u>
<u>7/26/2021</u>	<u>New Issuance</u>	<u>530,004</u>	<u>Common Stock</u>	<u>\$0.001</u>	<u>No</u>	<u>Eitan Ekstein</u>	<u>Conversion of loan</u>	<u>R</u>	<u>Exemption: Section 4(a)(2) of the Securities Act</u>
<u>7/26/2021</u>	<u>New Issuance</u>	<u>530,004</u>	<u>Common Stock</u>	<u>\$0.001</u>	<u>No</u>	<u>Isak Nathan Zulman</u>	<u>Conversion of loan</u>	<u>R</u>	<u>Exemption: Section 4(a)(2) of the Securities Act</u>
<u>7/26/2021</u>	<u>New Issuance</u>	<u>239,773</u>	<u>Common Stock</u>	<u>\$0.001</u>	<u>No</u>	<u>Shlomo Sabag</u>	<u>Conversion of loan</u>	<u>R</u>	<u>Exemption: Section 4(a)(2) of the Securities Act</u>
<u>7/26/2021</u>	<u>New Issuance</u>	<u>530,004</u>	<u>Common Stock</u>	<u>\$0.001</u>	<u>No</u>	<u>Gal Yadid</u>	<u>Conversion of loan</u>	<u>R</u>	<u>Exemption: Section 4(a)(2) of the</u>

									<u>Securities Act</u>
<u>7/26/2021</u>	<u>New Issuance</u>	<u>1,060,000</u>	<u>Common Stock</u>	<u>\$0.001</u>	<u>No</u>	<u>Shlomie Bierman</u>	<u>Conversion of loan</u>	<u>R</u>	<u>Exemption: Section 4(a)(2) of the Securities Act</u>
<u>7/26/2021</u>	<u>New Issuance</u>	<u>792,545</u>	<u>Common Stock</u>	<u>\$0.001</u>	<u>No</u>	<u>Yaakov Wallach</u>	<u>Conversion of loan</u>	<u>R</u>	<u>Exemption: Section 4(a)(2) of the Securities Act</u>
<u>7/26/2021</u>	<u>New Issuance</u>	<u>792,545</u>	<u>Common Stock</u>	<u>\$0.001</u>	<u>No</u>	<u>Abraham Pines</u>	<u>Conversion of loan</u>	<u>R</u>	<u>Exemption: Section 4(a)(2) of the Securities Act</u>
<u>7/26/2021</u>	<u>New Issuance</u>	<u>416,997</u>	<u>Common Stock</u>	<u>\$0.001</u>	<u>No</u>	<u>Yehoshua Landa</u>	<u>Conversion of loan</u>	<u>R</u>	<u>Exemption: Section 4(a)(2) of the Securities Act</u>
<u>7/26/2021</u>	<u>New Issuance</u>	<u>166,799</u>	<u>Common Stock</u>	<u>\$0.001</u>	<u>No</u>	<u>Nir Yadid</u>	<u>Conversion of loan</u>	<u>R</u>	<u>Exemption: Section 4(a)(2) of the Securities Act</u>
<u>7/26/2021</u>	<u>New Issuance</u>	<u>83,399</u>	<u>Common Stock</u>	<u>\$0.001</u>	<u>No</u>	<u>Rachel Maayan</u>	<u>Conversion of loan</u>	<u>R</u>	<u>Exemption: Section 4(a)(2) of the</u>

									<u>Securities Act</u>
<u>7/26/2021</u>	<u>New Issuance</u>	<u>792,545</u>	<u>Common Stock</u>	<u>\$0.001</u>	<u>No</u>	<u>Yosef Goldman</u>	<u>Conversion of loan</u>	<u>R</u>	<u>Exemption: Section 4(a)(2) of the Securities Act</u>
<u>11/30/2021</u>	<u>Conversion of all preferred B shares 1:8 ratio</u>	<u>16,000.00</u>	<u>Common Stock</u>	<u>\$0.001</u>	<u>No</u>	<u>All holders of Preferred B</u>	<u>Conversion of all Preferred B shares to common stock</u>	<u>R</u>	<u>Exemption: Section 4(a)(2) of the Securities Act</u>
Shares Outstanding on Date of This Report: <u>Ending Balance</u> <u>Ending Balance:</u> Date <u>June 30, 2022</u> Common: <u>28,050,165</u> Preferred: <u>0</u>									

Example: A company with a fiscal year end of December 31st, in addressing this item for its quarter ended June 30, 2021, would include any events that resulted in changes to any class of its outstanding shares from the period beginning on January 1, 2019 through June 30, 2021 pursuant to the tabular format above.

Use the space below to provide any additional details, including footnotes to the table above:

B. Debt Securities, Including Promissory and Convertible Notes

Use the chart and additional space below to list and describe all outstanding promissory notes, convertible notes, convertible debentures, or any other debt instruments that may be converted into a class of the issuer's equity securities.

Check this box if there are no outstanding promissory, convertible notes or debt arrangements: ☒

Date of Note Issuance	Outstanding Balance (\$)	Principal Amount at Issuance (\$)	Interest Accrued (\$)	Maturity Date	Conversion Terms (e.g. pricing mechanism for determining conversion of instrument to shares)	Name of Noteholder (entities must have individual with voting / investment control disclosed).	Reason for Issuance (e.g. Loan, Services, etc.)
_____	_____	_____	_____	_____	_____	_____	_____
_____	_____	_____	_____	_____	_____	_____	_____
_____	_____	_____	_____	_____	_____	_____	_____
_____	_____	_____	_____	_____	_____	_____	_____

Use the space below to provide any additional details, including footnotes to the table above:

4) Financial Statements

A. The following financial statements were prepared in accordance with:

- ☒ U.S. GAAP
☐ IFRS

B. The financial statements for this reporting period were prepared by (name of individual)⁴:

Name: Arie Gordashnikov
Title: CPA
Relationship to Issuer: Independent, no relationship

Provide the financial statements described below for the most recent fiscal year or quarter. For the initial disclosure statement (qualifying for Pink Current Information for the first time) please provide reports for the two previous fiscal years and any subsequent interim periods.

- C. Balance Sheet;
D. Statement of Income;
E. Statement of Cash Flows;
F. Statement of Retained Earnings (Statement of Changes in Stockholders' Equity)

⁴ The financial statements requested pursuant to this item must be prepared in accordance with US GAAP or IFRS by persons with sufficient financial skills.

- G. Financial notes; and
- H. Audit letter, if audited

You may either (i) attach/append the financial statements to this disclosure statement or (ii) file the financial statements through OTCIQ as a separate report using the appropriate report name for the applicable period end. (“Annual Report,” “Quarterly Report” or “Interim Report”).

If you choose to publish the financial statements in a separate report as described above, you must state in the accompanying disclosure statement that such financial statements are incorporated by reference. You may reference the document(s) containing the required financial statements by indicating the document name, period end date, and the date that it was posted to OTCIQ in the field below. Financial Statements must be compiled in one document.

Financial statement information is considered current until the due date for the subsequent report (as set forth in the qualifications section above). To remain qualified for Current Information, a company must post its Annual Report within 90 days from its fiscal year-end date and Quarterly Reports within 45 days of each fiscal quarter-end date.

5) Issuer's Business, Products and Services

The purpose of this section is to provide a clear description of the issuer's current operations. In answering this item, please include the following:

- A. Summarize the issuer's business operations (If the issuer does not have current operations, state "no operations")

The Company is a holding company.

- B. Please list any subsidiaries, parents, or affiliated companies.

Revium Recovery, Ltd., is a fully owned subsidiary.

- C. Describe the issuers' principal products or services.

The Company, through its Subsidiary, is currently focused on the development of a disruptive, methodical and novel proprietary Clinical Decision Support software (CDS) which will allow for measurement-based integrative-care for the treatment of addiction and other mental disorders including depression and PTSD. Revium Recovery's CDS combines comprehensive psychological and neurocognitive diagnostics, which allow for:

- more informed treatment decisions;
- individualized treatment programs;
- prediction of treatment success for each patient individually.

The Company's product is still under development stage. In addition, as of the date of this report, the Company is exploring acquiring rights to other novel technologies or solutions in the pharma or medical related fields which are designed to address currently unmet medical needs.

6) Issuer's Facilities

The goal of this section is to provide a potential investor with a clear understanding of all assets, properties or facilities owned, used or leased by the issuer and the extent in which the facilities are utilized.

In responding to this item, please clearly describe the assets, properties or facilities of the issuer, give the location of the principal plants and other property of the issuer and describe the condition of the properties. If the issuer does not have complete ownership or control of the property (for example, if others also own the property or if there is a mortgage on the property), describe the limitations on the ownership.

If the issuer leases any assets, properties or facilities, clearly describe them as above and the terms of their leases.

The Company leases offices in the Mindspace building in Herzliya, Israel on a monthly basis.

7) Company Insiders (Officers, Directors, and Control Persons)

The goal of this section is to provide an investor with a clear understanding of the identity of all the persons or entities that are involved in managing, controlling or advising the operations, business development and disclosure of the issuer, as well as the identity of any significant or beneficial shareholders.

Using the tabular format below, please provide information, as of the period end date of this report, regarding any person or entity owning 5% or more of any class of the issuer's securities, as well as any officer, and any director of the company, or any person that performs a similar function, regardless of the number of shares they own. **If any insiders listed are corporate shareholders or entities, provide the name and address of the person(s) beneficially owning or controlling such corporate shareholders, or the name and contact information (City, State) of an individual representing the corporation or entity in the note section.**

Name of Officer/Director or Control Person	Affiliation with Company (e.g. Officer Title /Director/Owner of more than 5%)	Residential Address (City / State Only)	Number of shares owned	Share type/class	Ownership Percentage of Class Outstanding	Note
<u>David Lazar</u>	<u>Director</u>	<u>Oceanside, NY</u>	<u>800,000</u>	<u>Common Stock</u>	<u>2.85%</u>	_____
<u>Yoram Drucker</u>	<u>Director, owner of more than 5%</u>	<u>Reut, Israel</u>	<u>3,520,000</u>	<u>Common Stock</u>	<u>12.55%</u>	_____
<u>Bierman Shlomie</u>	<u>Owner of more than 5%</u>	<u>Monsey, NY</u>	<u>2,820,000</u>	<u>Common Stock</u>	<u>10.05%</u>	_____

<u>Yaakov Safren</u>	<u>Owner of more than 5%</u>	<u>Beit Shemesh, Israel</u>	<u>2,780,000</u>	<u>Common Stock</u>	<u>9.91%</u>	_____
<u>SBDHEI LP</u>	<u>Owner of more than 5%</u>	<u>Beit Shemesh, Israel</u>	<u>5,840,000</u>	<u>Common Stock</u>	<u>20.82%</u>	<u>Held by David Safren</u> Beit Shemesh, Israel
<u>Yaakov Wallach</u>	<u>Owner of more than 5%</u>	<u>Jerusalem, Israel</u>	<u>1,442,545</u>	<u>Common Stock</u>	<u>5.14%</u>	
<u>Abraham Pines</u>	<u>Owner of more than 5%</u>	<u>London, United Kingdom</u>	<u>1,442,545</u>	<u>Common Stock</u>	<u>5.14%</u>	
<u>Inna Martin</u>	<u>CEO, Director</u>	<u>Tel Aviv, Israel</u>	=	=	=	
<u>Eyal Flom</u>	<u>Director</u>	<u>Kfar Saba, Israel</u>	=	=	=	
<u>Mordechai Jacobson</u>	<u>Director</u>	<u>Raanana, Israel</u>	=	=	=	
<u>Matti Munk</u>	<u>Director</u>	<u>Jerusalem, Israel</u>	=	=	=	
<u>Sheldon and Ruth Perl</u>	<u>Owner of more than 5%</u>	<u>Lawrence, NY</u>	<u>2,375,000</u>	<u>Common Stock</u>	<u>8.47%</u>	

8) Legal/Disciplinary History

A. Please identify whether any of the persons or entities listed above have, in the past 10 years, been the subject of:

1. A conviction in a criminal proceeding or named as a defendant in a pending criminal proceeding (excluding traffic violations and other minor offenses);

N/A

2. The entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred,

suspended or otherwise limited such person's involvement in any type of business, securities, commodities, or banking activities;

N/A

3. A finding or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, or a state securities regulator of a violation of federal or state securities or commodities law, which finding or judgment has not been reversed, suspended, or vacated; or

N/A

4. The entry of an order by a self-regulatory organization that permanently or temporarily barred, suspended, or otherwise limited such person's involvement in any type of business or securities activities.

N/A

- B. Describe briefly any material pending legal proceedings, other than ordinary routine litigation incidental to the business, to which the issuer or any of its subsidiaries is a party or of which any of their property is the subject. Include the name of the court or agency in which the proceedings are pending, the date instituted, the principal parties thereto, a description of the factual basis alleged to underlie the proceeding and the relief sought. Include similar information as to any such proceedings known to be contemplated by governmental authorities.

None

9) Third Party Providers

Please provide the name, address, telephone number and email address of each of the following outside providers:

Securities Counsel

Name: David Aboudi
Firm: Aboudi Legal Group PLLC
Address 1: 745 Fifth Ave., Suite 500
Address 2: New York, NY 10151
Phone: +972-52-398-3707
Email: david@aboudilegal.com

Accountant or Auditor

Name: Arie Gordashnikov
Firm: Yosef Shimony
Address 1: 5 Badner St., P.O. Box 8241
Address 2: Ramat Gan, Israel

Phone: +972-3-611-6629
Email: arie@shimony.com

Investor Relations

Name: _____
Firm: _____
Address 1: _____
Address 2: _____
Phone: _____
Email: _____

Other Service Providers

Provide the name of any other service provider(s) that **that assisted, advised, prepared or provided information with respect to this disclosure statement**. This includes counsel, broker-dealer(s), advisor(s) or consultant(s) or provided assistance or services to the issuer during the reporting period.

Name: _____
Firm: _____
Nature of Services: _____
Address 1: _____
Address 2: _____
Phone: _____
Email: _____

10) Issuer Certification

Principal Executive Officer:

The issuer shall include certifications by the chief executive officer and chief financial officer of the issuer (or any other persons with different titles but having the same responsibilities) in each Quarterly Report or Annual Report.

The certifications shall follow the format below:

I, Inna Martin certify that:

1. I have reviewed this Quarterly disclosure statement of Revium Recovery, Inc.;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the

financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

08/15/2022 [Date]

/S/ Inna Martin [CEO's Signature]

(Digital Signatures should appear as “/s/ [OFFICER NAME]”)

Principal Financial Officer:

I, Inna Martin certify that:

1. I have reviewed this Quarterly disclosure statement of Revium Recovery, Inc.;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

08/15/2022 [Date]

/S/ Inna Martin [CFO's Signature]

(Digital Signatures should appear as “/s/ [OFFIC

REVIUM RECOVERY, INC.

CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

AS OF JUNE 30, 2022

UNAUDITED

U.S. DOLLARS IN THOUSANDS

INDEX

	<u>Page</u>
Condensed Consolidated Balance Sheets	2
Condensed Consolidated statements of comprehensive loss	3
Condensed Consolidated statements of changes in equity	4
Condensed Consolidated statements of cash flows	5
Notes to Condensed consolidated financial statements	6-7

REVIUM RECOVERY, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

U.S. dollars in thousands (except share data)

	June 30, 2022	December 31, 2021
ASSETS		
CURRENT ASSETS:		
Cash and cash equivalents	\$ 328	\$ 874
Other Current assets	140	123
Total current assets	<u>468</u>	<u>997</u>
Property and equipment, net	2	3
	<u>2</u>	<u>3</u>
TOTAL ASSETS	<u>\$ 470</u>	<u>\$ 1,000</u>
LIABILITIES AND STOCKHOLDERS' EQUITY		
CURRENT LIABILITIES:		
Accounts payable	53	54
Other account payables	1	9
Convertible Notes	6 1	1
Total current liabilities	<u>55</u>	<u>64</u>
Commitments and Contingencies		
STOCKHOLDERS' EQUITY		
Common stock, par value \$0.001 per share; 250,000,000 shares authorized; 28,050,165 shares issued and outstanding as of June 30, 2022 and December 31, 2021	28	28
Additional paid in capital	4,528	4,335
Accumulated deficit	(4,141)	(3,427)
Total stockholders' equity	<u>415</u>	<u>936</u>
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	<u>\$ 470</u>	<u>\$ 1,000</u>

The accompanying notes are an integral part of these financial statements.

REVIUM RECOVERY INC.

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

U.S. dollars in thousands (except share and per share data)

	For the six months ended		For the three months ended	
	June 30,		June 30,	
	2022	2021	2022	2021
Operating expenses				
Research and development expenses	\$ 48	\$ 160	\$ 11	\$ 72
General and administrative expenses	638	322	248	140
Operating loss	686	482	259	212
Financial expenses, net	28	21	29	(5)
Net loss and comprehensive loss	\$ 714	\$ 503	\$ 288	\$ 207
Net loss per common share – basic and diluted	\$ 0.02	\$ 0.09	\$ 0.01	\$ 0.03
Weighted average common shares outstanding – basic and diluted	28,050,165	5,889,856	28,050,165	6,103,050

*) Less than 1 thousand

The accompanying notes are an integral part of these financial statements.

REVIUM RECOVERY, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (DEFICIT)

U.S. dollars in thousands (except share data)

	Common Stock: Shares	Common Stock: Amount	Additional Paid in Capital	Accumulated Deficit	Totals
Balance at January 1, 2022	28,050,165	\$ 28	\$ 4,335	\$ (3,427)	\$ 936
Stock based compensation	-	-	193	-	193
Comprehensive loss	-	-	-	(714)	(714)
Balance at June 30, 2022	<u>28,050,165</u>	<u>\$ 28</u>	<u>\$ 4,528</u>	<u>\$ (4,141)</u>	<u>\$ 409</u>

	Common Stock: Shares (*)	Common Stock: Amount	Preferred Stock: Shares	Preferred Stock: Amount	Additional Paid in Capital	Accumulated Deficit	Totals
Balance at January 1, 2021	4,678,050	\$ 5	2,000,000	\$ 20	\$ 2,855	\$ (1,627)	\$ 1,253
Issuance of shares and warrants	1,437,500	1	-	-	559	-	560
Comprehensive loss	-	-	-	-	-	(503)	(503)
Balance at June 30, 2021	<u>6,115,550</u>	<u>6</u>	<u>2,000,000</u>	<u>20</u>	<u>3,414</u>	<u>(2,130)</u>	<u>1,310</u>

	Common Stock: Shares	Common Stock: Amount	Additional Paid in Capital	Accumulated Deficit	Totals
Balance at April 1, 2022	28,050,165	\$ 28	\$ 4,442	\$ (3,853)	\$ 617
Stock based compensation	-	-	86	-	86
Comprehensive loss	-	-	-	(288)	(288)
Balance at June 30, 2022	<u>28,050,165</u>	<u>\$ 28</u>	<u>\$ 4,528</u>	<u>\$ (4,141)</u>	<u>\$ 409</u>

	Common Stock: Shares (*)	Common Stock: Amount	Preferred Stock: Shares	Preferred Stock: Amount	Additional Paid in Capital	Accumulated Deficit	Totals
Balance at April 1, 2021	6,053,050	\$ 6	2,000,000	\$ 20	\$ 3,389	\$ (1,923)	\$ 1,492
Issuance of shares and warrants	62,500	(*)	-	-	25	-	25
Comprehensive loss	-	-	-	-	-	(207)	(207)
Balance at June 30, 2021	<u>6,115,550</u>	<u>6</u>	<u>2,000,000</u>	<u>20</u>	<u>3,414</u>	<u>(2,130)</u>	<u>1,310</u>

The accompanying notes are an integral part of these financial statements.

REVIUM RECOVERY, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

U.S. dollars in thousands

	For the six months ended June 30,	
	2022	2021
CASH FLOWS FROM OPERATING ACTIVITIES:		
Net loss	\$ (713)	\$ (503)
Adjustments to reconcile net loss to net cash used in operating activities:		
Stock based compensation	193	-
Depreciation	1	*)
Interest expenses on convertible loan	-	2
Changes in assets and liabilities		
Other current assets	(17)	154
Other account payables	(8)	(173)
Accounts payable	(1)	52
NET CASH USED IN OPERATING ACTIVITIES	<u>(549)</u>	<u>(468)</u>
CASH FLOW FROM FINANCING ACTIVITIES:		
Issuance of Common stock and warrants	-	560
Receipt of convertible loans, net	-	-
NET CASH PROVIDED BY FINANCING ACTIVITIES	<u>-</u>	<u>560</u>
INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	(549)	92
CASH AND CASH EQUIVALENTS AT THE BEGINNING OF PERIOD	874	1,344
CASH AND CASH EQUIVALENTS AT THE END OF PERIOD	<u>\$ 328</u>	<u>\$ 1,436</u>

*) Less than 1 thousand.

The accompanying notes are an integral part of these financial statements.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

U.S. dollars in thousands, except share and per share data

NOTE 1 – GENERAL

- a. Revium Recovery, Inc. (the “**Company**” or “**Revium**”, formerly known as OC Beverage Inc.) was incorporated in the State of Delaware.

OC Beverages (private) was incorporated on March 26, 2008 and started operations on April 1, 2008. OC Beverages was a manufacturer of beverages. The company ceased operations in 2010.

On June 22, 2020 the Company formed an Israeli subsidiary named Revium Recovery Ltd. (the “Subsidiary”). On December 9, 2020, the Company changed name to “Revium Recovery Inc.”

The Company, through its Subsidiary, is currently focused on the development of a disruptive, methodical and novel proprietary Clinical Decision Support software (CDS) which will allow for measurement-based integrative-care for the treatment of addiction and other mental disorders including depression and PTSD. . Revium Recovery's CDS combines comprehensive psychological and neurocognitive diagnostics, which allow for:

- more informed treatment decisions;
- individualized treatment programs;
- prediction of treatment success for each patient individually.

The Company’s product is still under development stage. In addition, as of the date of this report, the Company is exploring acquiring rights to other novel technologies or solutions in the pharma or medical related fields which are designed to address currently unmet medical needs.

- b. Going concern uncertainty and management plans:

The Company has not yet generated any revenues from its current operations, and therefore is dependent upon external sources for financing its operations. As of June 30, 2022, the Company has an accumulated deficit of \$4,144.

Furthermore, the Company intends to continue to finance its operating activities by raising capital. Currently the Company has no commitments for such capital and there are no assurances that the Company will be successful in obtaining an adequate level of financing needed for its long-term research and development activities on commercially reasonable terms or at all.

If the Company will not have sufficient liquidity resources, the Company may not be able to continue the development of its product candidates or may be required to implement cost reduction measures and may be required to delay part of its development programs. The Company’s management and board of directors are of the opinion that its current financial resources will be sufficient to continue the development of the Company’s products for at least the next twelve months.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

U.S. dollars in thousands, except share and per share data

NOTE 2 – SIGNIFICANT ACCOUNTING POLICIES

Unaudited condensed consolidated financial statements:

These unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and accompanying notes for the year ended December 31, 2021. The significant accounting policies applied in the annual financial statements of the Company as of December 31, 2021, are applied consistently in these interim consolidated financial statements.

NOTE 3 – UNAUDITED CONDENSED FINANCIAL STATEMENTS

The accompanying condensed consolidated balance sheet as of June 30, 2022, the condensed consolidated statements of comprehensive loss and the condensed consolidated statements of cash flows for the six months ended June 30, 2022 and 2021, as well as the condensed consolidated statement of changes in equity for the six months ended June 30, 2022, are unaudited.

These unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (“U.S. GAAP”) and applicable rules and regulations of the Securities and Exchange Commission regarding interim financial reporting. In management’s opinion, the unaudited condensed consolidated financial statements include all adjustments of a normal recurring nature necessary for the fair presentation of the Company’s financial position as of June 30, 2022, as well as its results of operations and cash flows for the six and three months ended June 30, 2022 and 2021. The results of operations for the six months ended June 30, 2022 are not necessarily indicative of the results to be expected for the year ending December 31, 2022.